Paolo Tarantino, MD
LightNews LightNews
banner
ptarantinomd.bsky.social
Paolo Tarantino, MD
@ptarantinomd.bsky.social
2.2K followers 140 following 21 posts
Breast Medical Oncologist, Advanced Fellow Dana-Farber | Harvard | PhD Unimi. SoMe Editor ESMO Open. Interested in breast oncology, HER2, ADCs and good music.
Posts Replies Media Videos
Reposted by Paolo Tarantino, MD
jameabraham.bsky.social
Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social
May 13, 2025 at 10:06 PM
Reposted by Paolo Tarantino, MD
onclive.bsky.social
✨EXCLUSIVE PREVIEW: Ahead of the 2025 @ascocancer.bsky.social Annual Meeting, breast cancer experts highlight this year's most anticipated abstracts @stolaney1.bsky.social @ptarantinomd.bsky.social #ASCO25 #bcsm www.onclive.com/view/breast-...
May 14, 2025 at 12:17 PM
Reposted by Paolo Tarantino, MD
oncodaily.bsky.social
Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - Paolo Tarantino
@ptarantinomd.bsky.social
@stolaney1.bsky.social
@dfcibreastonc.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - OncoDaily
Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center / cancer, DFCI, OncoDaily, Oncology, Paolo Tarantino, Sara Tolaney
oncodaily.com
May 12, 2025 at 6:54 PM
Reposted by Paolo Tarantino, MD
oncodaily.bsky.social
Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador
@ptarantinomd.bsky.social
@myesmo.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOBreast25 #ESMO
Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador - OncoDaily
Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador / Breast Cancer, cancer, ESMO, ESMO Ambassadors, ESMO Breast 25, OncoDaily, Oncology, Paolo
oncodaily.com
May 13, 2025 at 9:58 PM
Reposted by Paolo Tarantino, MD
myesmo.bsky.social
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf
May 12, 2025 at 7:32 AM
Reposted by Paolo Tarantino, MD
dfcibreastonc.bsky.social
Congratulations to Drs. Paolo Tarantino, Caterina Sposetti, Pietro De Placido, and Tess O'Meara on receiving the prestigious #ConquerCancer #ASCO Merit Awards!
@ptarantinomd.bsky.social @csposettimd.bsky.social
April 25, 2025 at 12:43 PM
Reposted by Paolo Tarantino, MD
elizsmckenna.bsky.social
Don't miss "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development," a Cancer Discovery review by #AACR25 speakers Elisabeth de Vries and @raffcolo.bsky.social (along with Pat LoRusso & @ptarantinomd.bsky.social) doi.org/10.1158/2159...
April 26, 2025 at 4:00 PM
Reposted by Paolo Tarantino, MD
oncodaily.bsky.social
Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer
@ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #BreastCancer
Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer - OncoDaily
Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer / Breast Cancer, cancer, Dana-Farber Cancer Institute, OncoDaily,
oncodaily.com
April 23, 2025 at 9:27 PM
Reposted by Paolo Tarantino, MD
onclive.bsky.social
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
@ptarantinomd.bsky.social @danafarbernews.bsky.social #BreastCancer
www.onclive.com/view/novel-a...
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
www.onclive.com
April 21, 2025 at 6:52 PM
Reposted by Paolo Tarantino, MD
oncodaily.bsky.social
St. Gallen Consensus 2025 – 10 key votes - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#Cancer #Medicine #Health #BreastCancer #CancerConference #Oncology #OncoDaily
Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes - OncoDaily
Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes / Breast Cancer, breast oncology, cancer, Dana-Farber Cancer Institute, fight against cancer, G
oncodaily.com
March 24, 2025 at 9:29 PM
Reposted by Paolo Tarantino, MD
dfcibreastonc.bsky.social
Register for the @OncLive Breast Cancer State of the Science Summit at the Hilton Boston in Back Bay on March 26th, hosted by Dr. Paolo Tarantino @ptarantinomd.bsky.social. All are free to attend including doctors, nurses, pharmacists, clinical researchers, etc.
👉 event.onclive.com/QVZ54b?RefId...
March 13, 2025 at 5:13 PM
Reposted by Paolo Tarantino, MD
oncodaily.bsky.social
A pleasure to join the gender balance session at JSMO25 - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/blog/253704

#Cancer #CancerResearch #Medicine #Health #JSMO25 #Oncology #OncoDaily
Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 - OncoDaily
Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 / cancer, JSMO25, OncoDaily, Oncology, Paolo Tarantino
oncodaily.com
March 11, 2025 at 9:36 PM
ptarantinomd.bsky.social
2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.

Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
February 15, 2025 at 5:07 PM
Reposted by Paolo Tarantino, MD
dfcibreastonc.bsky.social
Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social
December 17, 2024 at 2:30 PM
Reposted by Paolo Tarantino, MD
itsnotpink.bsky.social
No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.)

For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.
ilanaschlam.bsky.social Ilana Schlam @ilanaschlam.bsky.social · Dec 13
Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 9:36 PM
Reposted by Paolo Tarantino, MD
erikahamilton9.bsky.social
Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 4:51 PM
Reposted by Paolo Tarantino, MD
ilanaschlam.bsky.social
Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social
December 12, 2024 at 1:50 PM
Reposted by Paolo Tarantino, MD
elisabettabonzano.bsky.social
📌“Optimizing outcomes for HER2-expressing breast cancer through novel biomarkers and TKIs”
Great discussion by @ptarantinomd.bsky.social 👏🏻
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF @danafarber.bsky.social
December 12, 2024 at 2:33 PM
ptarantinomd.bsky.social
‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added!

For the impatient ones, press release here: www.businesswire.com/news/home/20...

If you’re in San Anyonio, though, make sure to attend the data presentation today by Otto Metzger!
December 12, 2024 at 2:55 PM
Reposted by Paolo Tarantino, MD
dfcibreastonc.bsky.social
Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will serve as a moderator in the #SABCS24 Educational Session 7. He will also give a presentation titled “Aiming for the Target: Increasing the Precision of #ADCs through Novel Biomarkers and Innovative Molecular Constructs”
December 11, 2024 at 12:24 AM
Reposted by Paolo Tarantino, MD
elisabettabonzano.bsky.social
📌Education Session: People's Choice -The Future in Antibody Drug Conjugates
Topic 1: “The ABC of ADCs: History, Mechanism of Action, Mechanisms of Resistance” by John Lambert 👏🏻
Moderator Introduction by @ptarantinomd.bsky.social 👏🏻
#SABCS24 #day2 @oncoalert.bsky.social #OncoAlertAF
December 11, 2024 at 10:22 PM
Reposted by Paolo Tarantino, MD
dfcibreastonc.bsky.social
Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will be the invited discussant for Session 8: “Novel HER2 Therapeutics” at #SABCS24, his discussion will focus on #RadiationOncology.

🗓️ Thursday, December 12th
⏰ 7:30 - 7:45 am CST (8:30 – 8:45 am EST)
📍 Stars at Night 1-2
December 11, 2024 at 5:58 PM
ptarantinomd.bsky.social
Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?
December 11, 2024 at 2:13 PM
ptarantinomd.bsky.social
#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm
December 10, 2024 at 6:20 PM